Contrasting Immune Pharmaceuticals (IMNP) & Marinus Pharmaceuticals (MRNS)
Immune Pharmaceuticals (NASDAQ: IMNP) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation.
Valuation & Earnings
This table compares Immune Pharmaceuticals and Marinus Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Immune Pharmaceuticals||N/A||N/A||-$32.66 million||($6.87)||-0.13|
|Marinus Pharmaceuticals||N/A||N/A||-$28.64 million||($0.93)||-6.66|
Marinus Pharmaceuticals is trading at a lower price-to-earnings ratio than Immune Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Immune Pharmaceuticals has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 2.31, meaning that its share price is 131% more volatile than the S&P 500.
Insider & Institutional Ownership
3.4% of Immune Pharmaceuticals shares are held by institutional investors. Comparatively, 23.6% of Marinus Pharmaceuticals shares are held by institutional investors. 6.7% of Immune Pharmaceuticals shares are held by company insiders. Comparatively, 6.4% of Marinus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This table compares Immune Pharmaceuticals and Marinus Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent recommendations for Immune Pharmaceuticals and Marinus Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Marinus Pharmaceuticals has a consensus target price of $11.00, indicating a potential upside of 77.71%. Given Marinus Pharmaceuticals’ higher possible upside, analysts plainly believe Marinus Pharmaceuticals is more favorable than Immune Pharmaceuticals.
Marinus Pharmaceuticals beats Immune Pharmaceuticals on 8 of the 9 factors compared between the two stocks.
Immune Pharmaceuticals Company Profile
Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.
Receive News & Ratings for Immune Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.